Additional evidence of complement activation following SARS-CoV-2 infection includes the observation of increased plasma levels of complement markers, such as sC5b-9, C5a, and C3a, in COVID-19 patients compared to non-COVID-19 and healthy controls, and their association with disease severity (20–22). Here, C3 is linked to COVID-19.